http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 17:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+18++Filed+by%3A+Pereira+Brian+JG/26957069.html si-local-file:///var/storage/secattach/20260820/26957069.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+18++Filed+by%3A+Pereira+Brian+JG/26957069.html Thu, 20 Aug 2026 17:01:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+18++Filed+by%3A+Pereira+Brian+JG/26957069.html si-local-file:///var/storage/secattach/20260820/26957069.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+18++Filed+by%3A+Pereira+Brian+JG/26957069.html Thu, 20 Aug 2026 17:01:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26945000.html si-local-file:///var/storage/secattach/20260818/26945000.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26945000.html Tue, 18 Aug 2026 16:42:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26945000.html si-local-file:///var/storage/secattach/20260818/26945000.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26945000.html Tue, 18 Aug 2026 16:42:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26944984.html si-local-file:///var/storage/secattach/20260818/26944984.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26944984.html Tue, 18 Aug 2026 16:41:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26944984.html si-local-file:///var/storage/secattach/20260818/26944984.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+Pereira+Brian+JG/26944984.html Tue, 18 Aug 2026 16:41:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26912430.html si-local-file:///var/storage/secattach/20260812/26912430.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26912430.html Wed, 12 Aug 2026 15:45:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26912430.html si-local-file:///var/storage/secattach/20260812/26912430.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROKIDNEY+CORP.++++++++++++++++++++++++Filed+by%3A+MORGAN+STANLEY/26912430.html Wed, 12 Aug 2026 15:45:00 -0400 O.49464338 PROK http://www.streetinsider.com/Earnings/ProKidney+Corp+%28PROK%29+Misses+Q2+EPS+by+1c/26899382.html <p>ProKidney Corp (NASDAQ: PROK) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $129.75 thousand.</p><p>For earnings history and earnings-related data on ProKidney Corp (PROK) <a href="http://www.streetinsider.com/ec_earnings.php?q=PROK">click here</a>.</p> http://www.streetinsider.com/Earnings/ProKidney+Corp+%28PROK%29+Misses+Q2+EPS+by+1c/26899382.html Mon, 10 Aug 2026 17:38:34 -0400 PROK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+10/26898013.html si-local-file:///var/storage/secattach/20260810/26898013.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+10/26898013.html Mon, 10 Aug 2026 16:12:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+10/26898013.html si-local-file:///var/storage/secattach/20260810/26898013.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+10/26898013.html Mon, 10 Aug 2026 16:12:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROKIDNEY+CORP.+++++++++++For%3A+Jun+30/26897977.html si-local-file:///var/storage/secattach/20260810/26897977.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROKIDNEY+CORP.+++++++++++For%3A+Jun+30/26897977.html Mon, 10 Aug 2026 16:11:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROKIDNEY+CORP.+++++++++++For%3A+Jun+30/26897977.html si-local-file:///var/storage/secattach/20260810/26897977.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROKIDNEY+CORP.+++++++++++For%3A+Jun+30/26897977.html Mon, 10 Aug 2026 16:11:00 -0400 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Press+Releases/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html <ul><li><em>Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027</em></li><li><em>On track for completion of full enrollment for PROACT 1 in the second half of 2026</em></li><li><em>Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&amp;D, CMC and supply chain leadership experience</em></li><li><em>Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027</em></li></ul> <p align="justify">WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- <strong>ProKidney Corp. (Nasdaq: PROK) </strong>(“ProKidney” or the “Company”), a leading http://www.streetinsider.com/Globe+Newswire/ProKidney+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26897720.html Mon, 10 Aug 2026 16:05:00 -0400 A.32112375 O.00052389 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+04++Filed+by%3A+Pereira+Brian+JG/26879439.html si-local-file:///var/storage/secattach/20260806/26879439.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+04++Filed+by%3A+Pereira+Brian+JG/26879439.html Thu, 06 Aug 2026 08:09:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+04++Filed+by%3A+Pereira+Brian+JG/26879439.html si-local-file:///var/storage/secattach/20260806/26879439.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Aug+04++Filed+by%3A+Pereira+Brian+JG/26879439.html Thu, 06 Aug 2026 08:09:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Jul+01++Filed+by%3A+Locke+Kenneth+Thomas/26735335.html si-local-file:///var/storage/secattach/20260706/26735335.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Jul+01++Filed+by%3A+Locke+Kenneth+Thomas/26735335.html Mon, 06 Jul 2026 16:02:00 -0400 O.49464338 PROK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Jul+01++Filed+by%3A+Locke+Kenneth+Thomas/26735335.html si-local-file:///var/storage/secattach/20260706/26735335.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROKIDNEY+CORP.+++++++++++For%3A+Jul+01++Filed+by%3A+Locke+Kenneth+Thomas/26735335.html Mon, 06 Jul 2026 16:02:00 -0400 O.49464338 PROK